ProCE Banner Events

Share

Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course

Join us for this dynamic, case-based, live symposium in collaboration with the NCCN to hear from an expert panel on current recommendations and emerging strategies for treating patients with CLL. Sign up now!

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Evaluation link: https://education.nccn.org/CLLChicago2025

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Registered Nurses: 1.50 Nursing contact hour

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Who Should Attend

This activity is intended for oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Time and location

Friday, May 30, 2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Salon A5

Agenda

Registration and Dinner: 6:30 PM - 7:00 PM CT

Symposium: 7:00 PM - 8:30 PM CT

 

Welcome and Introduction

Applying New Advances in Frontline CLL/SLL Therapy: Aligning Clinical Evidence with Current NCCN Guidelines and Expert Recommendations

Audience Question and Answer Session

Individualized Therapy Sequence and Management Approaches to Optimize Survival and Quality of Life in R/R CLL/SLL

Audience Question and Answer Session

Roundtable Panel Discussion on Key Current Issues in CLL/SLL Treatment

Final Thoughts

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Room Name

Salon A5

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 

Target Audience
This activity is intended for oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, considering the available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration of treatment (continuous vs. fixed duration), and patient preference
  • Evaluate intraclass differences in selectivity, binding, efficacy, and adverse event profiles of targeted agents used to treat CLL/SLL
  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g., assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for treatment)
  • Identify patients with CLL/SLL who may be eligible for allogeneic HCT or enrollment in a clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-25-045-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

NCCN 2020
CCO 2022

Supporter

Supported by an independent medical education grant from AbbVie. Supported by educational grants from Bristol Myers Squibb and Lilly.

AbbVie Inc.

Bristol Myers Squibb

Lilly

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.